Try our beta test site

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

This study has been terminated.
(insufficient enrollment and retention)
Sponsor:
Collaborators:
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Alp Ikizler, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00878969
First received: April 8, 2009
Last updated: January 18, 2016
Last verified: January 2016
Results First Received: November 20, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Health Services Research
Conditions: Oxidative Stress
Endothelial Dysfunction
Interventions: Drug: valsartan (ARB)
Drug: ramipril (ACE inhibitor)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study was conducted at the Vanderbilt University Medical Center and at the University of Washington between January 2010 and June 2015.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
There is a 3-week period between enrollment and assignment to treatment group. This "washout" period is to ensure that no blood pressure medicines (ARBs or ACE inhibitors) are left in the body. Although 123 subjects were enrolled, only 78 were assigned to a treatment group (45 subjects were screen failures).

Reporting Groups
  Description
Valsartan 80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
Ramipril 2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
Placebo matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months

Participant Flow:   Overall Study
    Valsartan   Ramipril   Placebo
STARTED   25   27   26 
COMPLETED   10   12   15 
NOT COMPLETED   15   15   11 
Physician Decision                5                3                2 
Withdrawal by Subject                1                6                3 
kidney transplant                2                3                2 
Adverse Event                3                1                2 
Lost to Follow-up                2                1                0 
Protocol Violation                2                0                0 
Death                0                0                2 
Pregnancy                0                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Valsartan 80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
Ramipril 2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 6 mg of ramipril taken orally on a daily basis for 18 months
Placebo matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
Total Total of all reporting groups

Baseline Measures
   Valsartan   Ramipril   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 25   27   26   78 
Age 
[Units: Years]
Mean (Standard Deviation)
 53  (13)   53  (13)   49  (9)   52  (12) 
Gender 
[Units: Participants]
       
Female   11   8   9   28 
Male   14   19   17   50 
Ethnicity (NIH/OMB) 
[Units: Participants]
       
Hispanic or Latino   3   6   1   10 
Not Hispanic or Latino   22   21   25   68 
Unknown or Not Reported   0   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
       
American Indian or Alaska Native   0   0   0   0 
Asian   0   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0   0 
Black or African American   13   16   15   44 
White   10   7   9   26 
More than one race   0   0   0   0 
Unknown or Not Reported   2   4   2   8 
Region of Enrollment 
[Units: Participants]
       
United States   25   27   26   78 


  Outcome Measures

1.  Primary:   Interleukin-6 (IL-6)   [ Time Frame: baseline and 18 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: T. Alp Ikizler, MD
Organization: Vanderbilt University
phone: 615-343-6104
e-mail: alp.ikizler@vanderbilt.edu



Responsible Party: Alp Ikizler, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00878969     History of Changes
Other Study ID Numbers: Fibrinolysis in Dialysis Aim 3
R01HL065193-08A2 ( US NIH Grant/Contract Award Number )
Study First Received: April 8, 2009
Results First Received: November 20, 2015
Last Updated: January 18, 2016